Aug 20, 2025
Andrea James, Chief Financial Officer at iMDx, is focused on expanding access to innovative molecular diagnostic testing staring with a test for monitoring transplanted organ health. The test measures the donor-derived cell-free DNA which can indicate the need for drugs to target organ rejection before invasive procedures are required. The company is developing a kit-based version of the test that can be run by hospitals rather than relying on centralized labs, to increase access to this diagnostic and improve transplant outcomes.
Andrea explains, "We changed our name on June 17th from OncoCyte, as you had just referenced, to Insight Molecular Diagnostics Inc. We're now going by iMDx, and our mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes."
"We actually have three pieces of IP, intellectual property, and we are initially commercializing in transplant. So we measure a biomarker called donor-derived cell-free DNA, don't get too hung up on it. That's a lot of words. It basically looks for fragments of DNA in the blood, which can indicate transplanted organ damage and therefore rejection. And so that is where we are commercializing first."
"What's really interesting is that the innovations in this space are, okay, so let's say you've been on dialysis, that's a really tough life. You finally get your transplanted kidney, and now let's say your body is starting to reject it. You're one of those one in five who were a match, your kidney was a match for you, but then your immune system is attacking it anyway. That used to be almost a death sentence."
"Your options there were you're going to lose your kidney, you go back on dialysis, or you lose your life. But now there are therapies that are coming out to treat antibody-mediated rejection, or AMR, and our test is being used to monitor the efficacy of those therapies."
#iMDx #MolecularDiagnostics #Molecular #Diagnostics #Healthcare #PrecisionMedicine #Genomics #Decentralized #LiquidBiopsy #DigitalPCR #Transplant #Localization #Labs #PointOfCareTesting #RapidCare #Democratization
